Home › Chronic Lymphocytic Leukemia
Pag-aaral pangklinika para sa Chronic Lymphocytic Leukemia na nagre-recruit sa U.S.
122 pag-aaral para sa Chronic Lymphocytic Leukemia ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Boston, MA32 pag-aaral
- Columbus, OH29 pag-aaral
- Durham, NC27 pag-aaral
- Washington, DC22 pag-aaral
- Seattle, WA21 pag-aaral
- Rochester, MN19 pag-aaral
- New York City, NY18 pag-aaral
- Houston, TX17 pag-aaral
- Baldwin Park, CA16 pag-aaral
- Milwaukee, WI14 pag-aaral
- Chicago, IL14 pag-aaral
- Cincinnati, OH14 pag-aaral
- Nashville, TN13 pag-aaral
- Atlanta, GA11 pag-aaral
- Jacksonville, FL11 pag-aaral
- Philadelphia, PA11 pag-aaral
- Kansas City, MO10 pag-aaral
- Portland, OR10 pag-aaral
- Pittsburgh, PA10 pag-aaral
- San Diego, CA10 pag-aaral
- Salt Lake City, UT10 pag-aaral
- Dallas, TX10 pag-aaral
- Charlotte, NC9 pag-aaral
- Miami, FL9 pag-aaral
- Queens, NY8 pag-aaral
- Omaha, NE8 pag-aaral
- Los Angeles, CA8 pag-aaral
- Minneapolis, MN8 pag-aaral
- Winston-Salem, NC8 pag-aaral
- Tampa, FL8 pag-aaral
- St. Louis, MO8 pag-aaral
- Denver, CO8 pag-aaral
- Des Moines, IA8 pag-aaral
- Billings, MT7 pag-aaral
- Fort Wayne, IN7 pag-aaral
- Aurora, CO7 pag-aaral
- Cleveland, OH7 pag-aaral
- Eugene, OR7 pag-aaral
- Clifton, NJ7 pag-aaral
- Mountain View, CA7 pag-aaral
Ayos sa estado
- Alabama7 pag-aaral
- Arizona14 pag-aaral
- Arkansas4 pag-aaral
- California34 pag-aaral
- Colorado16 pag-aaral
- Connecticut5 pag-aaral
- Delaware4 pag-aaral
- District of Columbia4 pag-aaral
- Florida34 pag-aaral
- Georgia16 pag-aaral
- Idaho4 pag-aaral
- Illinois17 pag-aaral
- Indiana12 pag-aaral
- Iowa10 pag-aaral
- Kansas6 pag-aaral
- Kentucky7 pag-aaral
- Louisiana6 pag-aaral
- Maine6 pag-aaral
- Maryland23 pag-aaral
- Massachusetts34 pag-aaral
- Michigan12 pag-aaral
- Minnesota29 pag-aaral
- Mississippi5 pag-aaral
- Missouri13 pag-aaral
- Montana7 pag-aaral
- Nebraska8 pag-aaral
- Nevada6 pag-aaral
- New Hampshire3 pag-aaral
- New Jersey13 pag-aaral
- New Mexico3 pag-aaral
- New York26 pag-aaral
- North Carolina34 pag-aaral
- Ohio44 pag-aaral
- Oklahoma4 pag-aaral
- Oregon17 pag-aaral
- Pennsylvania22 pag-aaral
- Rhode Island5 pag-aaral
- South Carolina5 pag-aaral
- South Dakota4 pag-aaral
- Tennessee17 pag-aaral
- Texas38 pag-aaral
- Utah10 pag-aaral
- Virginia11 pag-aaral
- Washington27 pag-aaral
- Wisconsin19 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06846671Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Nagre-recruitPhase 2
Edad 75 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07685717A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06697184A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06943872A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06973187A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT00923507Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT04269902A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07277231A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06136559Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Nagre-recruitPhase 2
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT03986034Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06784167Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT01087333A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07221500Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT07194980Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT07061951Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT04169737Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07225439A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05091424Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT03666000A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06564038Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT04588922Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.